Naringenin has been proven to strongly bind with AKT1 and EGFR, which can regulate the EGFR-PI3K-Akt signaling pathway and ERK/MAPK signaling pathway to inhibit the production of reactive oxygen species (ROS) and the activation of NF-κB, which finally inhibits the expression of MUC5AC, thus inhibiting lung cancer (Figure 4C) [103]. This evidence concerns the gene AKT1 and lung carcinoma.